Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Katherine V. Barnes is active.

Publication


Featured researches published by Katherine V. Barnes.


Proceedings of the National Academy of Sciences of the United States of America | 2014

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome

Omar Khwaja; Eugenia Ho; Katherine V. Barnes; Heather M. O’Leary; Luis M. Pereira; Yaron Finkelstein; Charles A. Nelson; Vanessa Vogel-Farley; Geneva DeGregorio; Ingrid A. Holm; Umakanth Khatwa; Kush Kapur; Mark E. Alexander; Deirdre M. Finnegan; Nicole G. Cantwell; Alexandra C. Walco; Leonard Rappaport; Matt Gregas; Raina N. Fichorova; Michael Shannon; Mriganka Sur; Walter E. Kaufmann

Significance This paper provides unique insights into mechanism-based therapeutics for Rett syndrome (RTT), a devastating neurodevelopmental disorder. This clinical trial was based on pioneer preclinical work from the laboratory of M.S. Outcome measures include clinical instruments, standardized behavioral measures, and biomarkers, the latter being not only objective but also applicable to experimental studies. We believe this work will a have major impact on the understanding and treatment of RTT, as well as other neurodevelopmental disorders. Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulin-like growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-wk multiple ascending dose (MAD) (40–120 μg/kg twice daily) period and a 20-wk open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.


Developmental Medicine & Child Neurology | 2011

Spectrum of neurodevelopmental disabilities in children with cerebellar malformations

Marie-Eve Bolduc; Adré J. du Plessis; Nancy Sullivan; Omar Khwaja; Xun Zhang; Katherine V. Barnes; Richard L. Robertson; Catherine Limperopoulos

Aim  Advances in perinatal care and neuroimaging techniques have increased the detection of cerebellar malformations (CBMs) in the fetus and young infant. As a result, this has necessitated a greater understanding of the neurodevelopmental consequences of CBMs on child development. The aim of this study was to delineate the impact of CBMs on long‐term neurodevelopmental outcomes.


Annals of Neurology | 2010

Rett syndrome diagnostic criteria: Lessons from the Natural History Study

Alan K. Percy; Jeffrey L. Neul; Daniel G. Glaze; Kathleen J. Motil; Steven A. Skinner; Omar Khwaja; Hye Seung Lee; Jane B. Lane; Judy O. Barrish; Fran Annese; Lauren McNair; Joy Graham; Katherine V. Barnes

Analysis of 819 participants enrolled in the Rett syndrome (RTT) Natural History Study validates recently revised diagnostic criteria. 765 females fulfilled 2002 consensus criteria for classic (653/85.4%) or variant (112/14.6%) RTT. All participants classified as classic RTT fulfilled each revised main criterion; supportive criteria were not uniformly present. All variant RTT participants met at least 3 of 6 main criteria in the 2002, 2 of 4 main criteria in the current format, and 5 of 11 supportive criteria in both. This analysis underscores the critical role of main criteria for classic RTT; variant RTT requires both main and supportive criteria. Ann Neurol 2010


Neurology | 2011

Clinical severity and quality of life in children and adolescents with Rett syndrome

Jane B. Lane; H-S Lee; L.W. Smith; P. Cheng; Alan K. Percy; Daniel G. Glaze; Jeffrey L. Neul; Kathleen J. Motil; Judy O. Barrish; Steve A. Skinner; Fran Annese; Lauren McNair; Joy Graham; Omar Khwaja; Katherine V. Barnes; Jeffrey P. Krischer

Objective: The clinical features and genetics of Rett syndrome (RTT) have been well studied, but examination of quality of life (QOL) is limited. This study describes the impact of clinical severity on QOL among female children and adolescents with classic RTT. Methods: Cross-sectional and longitudinal analyses were conducted on data collected from an NIH-sponsored RTT natural history study. More than 200 participants from 5 to 18 years of age with classic RTT finished their 2-year follow-up at the time of analysis. Regression models after adjustment for their MECP2 mutation type and age at enrollment were used to examine the association between clinical status and QOL. Results: Severe clinical impairment was highly associated with poor physical QOL, but worse motor function and earlier age at onset of RTT stereotypies were associated with better psychosocial QOL; conversely, better motor function was associated with poorer psychosocial QOL. Conclusions: Standard psychosocial QOL assessment for children and adolescents with RTT differs significantly with regard to their motor function severity. As clinical trials in RTT emerge, the Child Health Questionnaire 50 may represent one of the important outcome measures.


Annals of Neurology | 2015

Visual evoked potentials detect cortical processing deficits in Rett syndrome.

Jocelyn LeBlanc; Geneva DeGregorio; Eleonora Centofante; Vanessa Vogel-Farley; Katherine V. Barnes; Walter E. Kaufmann; Michela Fagiolini; Charles A. Nelson

Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutation of the X‐linked MECP2 gene and characterized by developmental regression during the first few years of life. The objective of this study was to investigate if the visual evoked potential (VEP) could be used as an unbiased, quantitative biomarker to monitor brain function in RTT.


Journal of Neurodevelopmental Disorders | 2015

Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales

Katherine V. Barnes; Francesca R. Coughlin; Heather M. O’Leary; Natalie Bruck; Grace A. Bazin; Emily B. Beinecke; Alexandra C. Walco; Nicole G. Cantwell; Walter E. Kaufmann

BackgroundRett syndrome (RTT) is a severe neurodevelopmental disorder characterized by regression of language and motor skills, cognitive impairment, and frequent seizures. Although the diagnostic criteria focus on communication, motor impairments, and hand stereotypies, behavioral abnormalities are a prevalent and disabling component of the RTT phenotype. Among these problematic behaviors, anxiety is a prominent symptom. While the introduction of the Rett Syndrome Behavioral Questionnaire (RSBQ) represented a major advancement in the field, no systematic characterization of anxious behavior using the RSBQ or other standardized measures has been reported.MethodsThis study examined the profiles of anxious behavior in a sample of 74 girls with RTT, with a focus on identifying the instrument with the best psychometric properties in this population. The parent-rated RSBQ, Anxiety, Depression, and Mood Scale (ADAMS), and Aberrant Behavior Checklist-Community (ABC-C), two instruments previously employed in children with neurodevelopmental disorders, were analyzed in terms of score profiles, relationship with age and clinical severity, reliability, concurrent validity, and functional implications. The latter were determined by regression analyses with the Vineland Adaptive Behavior Scales-Second Edition (Vineland-II) and the Child Health Questionnaire (CHQ), a quality of life measure validated in RTT.ResultsWe found that scores on anxiety subscales were intermediate in range with respect to other behavioral constructs measured by the RSBQ, ADAMS, and ABC-C. Age did not affect scores, and severity of general anxiety was inversely correlated with clinical severity. We demonstrated that the internal consistency of the anxiety-related subscales were among the highest. Test-retest and intra-rater reliability was superior for the ADAMS subscales. Convergent and discriminant validity were measured by inter-scale correlations, which showed the best profile for the social anxiety subscales. Of these, only the ADAMS Social Avoidance showed correlation with quality of life.ConclusionsWe conclude that anxiety-like behavior is a prominent component of RTT’s behavioral phenotype, which affects predominantly children with less severe neurologic impairment and has functional consequences. Based on available data on standardized instruments, the ADAMS and in particular its Social Avoidance subscale has the best psychometric properties and functional correlates that make it suitable for clinical and research applications.


Annals of clinical and translational neurology | 2018

Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome

Heather M. O'Leary; Walter E. Kaufmann; Katherine V. Barnes; Kshitiz Rakesh; Kush Kapur; Daniel C. Tarquinio; Nicole G. Cantwell; Katherine J. Roche; Suzanne A. Rose; Alexandra C. Walco; Natalie M. Bruck; Grace A. Bazin; Ingrid A. Holm; Mark E. Alexander; Lindsay C. Swanson; Lauren M. Baczewski; Juan M. Mayor Torres; Charles A. Nelson; Mustafa Sahin

To measure the efficacy of mecasermin (recombinant human insulin‐like growth factor 1, rhIGF‐1), for treating symptoms of Rett syndrome (RTT) in a pediatric population using a double‐blind crossover study design.


Developmental Neurorehabilitation | 2017

Detecting autonomic response to pain in Rett syndrome

Heather M. O’Leary; Peter B. Marschik; Omar Khwaja; Eugenia Ho; Katherine V. Barnes; Tessa Clarkson; Natalie M. Bruck; Walter E. Kaufmann

Abstract Objective: To quantify pain response in girls affected by Rett syndrome (RTT) using electrodermal activity (EDA), a measure of skin conductance, reflecting sympathetic activity known to be modulated by physical and environmental stress. Methods: EDA increase, heart rate (HR) increase and Face Legs Activity Cry Consolability (FLACC) values calculated during venipuncture (invasive) and vital signs collection (non-invasive) events were compared with values calculated during a prior baseline and a RTT clinical severity score (CSS). Results: EDA and HR increase were significantly higher than baseline during venipuncture only and not significantly correlated with FLACC or CSS. EDA increase was the most sensitive measure of pain response. Conclusions: These preliminary findings revealed that motor impairment might bias non-verbal pain scales, underscore the importance of using autonomic measures when assessing pain and warrant further investigation into the utility of using EDA to objectively quantify RTT pain response to inform future RTT pain management.


Intellectual and Developmental Disabilities | 2017

Adapting the Mullen Scales of Early Learning for a Standardized Measure of Development in Children with Rett Syndrome.

Tessa Clarkson; Jocelyn LeBlanc; Geneva DeGregorio; Vanessa Vogel-Farley; Katherine V. Barnes; Walter E. Kaufmann; Charles A. Nelson

Rett Syndrome (RTT) is characterized by severe impairment in fine motor (FM) and expressive language (EL) function, making accurate evaluations of development difficult with standardized assessm ents. In this study, the administration and scoring of the Mullen Scales of Early Learning (MSEL) were adapted to eliminate the confounding effects of FM and EL impairments in assessing development. Forty-seven girls with RTT were assessed with the Adapted-MSEL (MSEL-A), a subset (n = 30) was also assessed using the Vineland Adaptive Behavior Scales-Second Edition (Vineland-II) and a further subset (n = 17) was assessed using an eye-tracking version of the MSEL (MSEL-ET). Participants performed better on the visual reception (VR) and receptive language (RL) domains compared to the FM and EL domains on the MSEL-A. Individual performance on each domain was independent of other domains. Corresponding MSEL-A and Vineland-II domains were significantly correlated. The MSEL-ET was as accurate as the MSEL-A in assessing VR and RL, yet took a 44% less time. Results suggested that the MSEL-A and the MSEL-ET could be viable measures for accurately assessing developmental domains in children with RTT.


Journal of Primary Care & Community Health | 2015

Long-acting reversible contraceptive use in urban women from a title X-supported Boston community health center.

Hope A. Ricciotti; Laura E. Dodge; Christina I. Ramirez; Katherine V. Barnes; Michele R. Hacker

Background: Unintended and adolescent pregnancy disproportionately affects minority populations, but the effect of age, race and ethnicity on the use of long-acting reversible contraception (LARC) has not been well studied. Objective: The objective of this pilot study was to examine LARC use over a 5-year period among women receiving care at a Boston community health center. Methods: Retrospective cohort study of LARC method use among black, Hispanic, and white women receiving care at the Dimock Center from 2006 to 2010. Results: This study included 276 women (60.1% black, 18.5% Hispanic, and 9.1% white). LARC was not used as a first-line method in the majority (96.0%), regardless of age, race, and ethnicity; yet nearly half identified a long-acting contraceptive as their method of choice. Conclusions: The findings of this pilot study reveal opportunities to reduce unintended pregnancy through increased LARC use, which may be accomplished by provider and patient education.

Collaboration


Dive into the Katherine V. Barnes's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alan K. Percy

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel G. Glaze

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Fran Annese

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Jane B. Lane

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Jeffrey L. Neul

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Judy O. Barrish

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Kathleen J. Motil

Baylor College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge